FCGR2A and neoplasm: These findingsprovide experimental support for the hypothesis that Siglecs can inhibitFcγR-mediated myeloid cell activation toward tumor cells ortumor-targeting antibodies by binding to sialylated ligands on tumorcells and inhibiting FcγR activation.27 Thus, these findings further demonstrate that Siglecs serve as excellenttargets for immune therapy and can be used for the development ofcancer immunotherapies.